<DOC>
	<DOCNO>NCT02682407</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability OMS721 subject IgA Nephropathy ( IgAN ) , Lupus Nephritis ( LN ) , Membranous Nephropathy ( MN ) , C3 Glomerulopathy ( C3G ) , include Dense Deposit Disease . The study also evaluate Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) , anti-drug antibody response ( ADA ) , neutralize antibody ( Nab ) .</brief_summary>
	<brief_title>Safety Study IgAN , LN , MN , &amp; C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721</brief_title>
	<detailed_description>This Phase 2 , multicenter study OMS721 subject follow disease : IgA Nephropathy ( IgAN ) , Lupus Nephritis , Membranous Nephropathy ( MN ) , C3 Glomerulopathy , include Dense Deposit Disease . Two cohort enrol . Cohort 1 subject corticosteroid dependent IgAN , LN , MN , C3 Glomerulopathy . Cohort 1 subject receive OMS721 uncontrolled , open-label design . Cohort 2 subject IgA nephropathy receiving corticosteroid . This cohort randomize receive either OMS721 treatment D5W vehicle randomize double-blind design . Approximately 26 subject enrol ( 16 Cohort 1 10 Cohort 2 ) .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Glomerulonephritis , Membranoproliferative</mesh_term>
	<criteria>Are least 18 year age Have diagnosis : IgAN , Lupus Nephritis , MN , C3 Glomerulopathy include Dense Deposit Disease Have average urine albumin/creatinine ratio &gt; 600 mg/g three sample collect consecutively daily prior 2 visit screen period For subject Cohort 1 , â‰¥ 10 mg prednisone equivalent dose least 12 week prior Screening If immunosuppressive treatment ( e.g. , cyclophosphamide , mycophenolate mofetil ) , stable dose least 2 month prior Screening Visit 1 expect change dose study duration eGFR &gt; = 30 mL/min/1.73 m2 calculate MDRD equation Are physiciandirected , stable , optimized treatment angiotensin convert enzyme inhibitor ( ACEI ) and/or angiotensin receptor blocker ( ARB ) systolic blood pressure &lt; 150 mmHg diastolic blood pressure &lt; 90 mmHg rest Have hemoglobin &lt; 9.0 g/dL Have platelet count &lt; 100,000/mm3 Have absolute neutrophil count &lt; 500 cells/mm3 Have ALT AST &gt; 3.0 x upper limit normal Have systemic manifestation HenochSchonlein purpura within 2 year prior Screening Have use : belimumab , eculizumab , rituximab within 6 month prior Screening Have history renal transplant Have diagnosis human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C infection , positive serology Screening Have infection require antibiotic treatment Screening Have malignancy except adequately treat cured basal squamous cell skin cancer , curatively treat situ disease , cancer patient diseasefree 5 year Have expectation survival le 6 month For subject Cohort 2 , receive corticosteroid within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>IgAN</keyword>
	<keyword>MN</keyword>
	<keyword>C3 Glomerulopathy</keyword>
	<keyword>Lupus Nephritis</keyword>
</DOC>